Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Intradermal Hepatitis B Vaccination In Patients With Advanced Chronic Renal Failure: Immunogenicity And Follow-up.
Author: Morais, E O
Resende, M R
Oliveira, A M
Sinkoc, V M
Garcia, M T
Angerami, R N
da Silva, L J
Abstract: Patients undergoing dialysis usually have a poor response to conventional hepatitis B vaccination. To observe the effects of intradermal hepatitis B (HB) vaccination in a 13-month prospective study of adult patients with end-stage renal failure. The patients were with or without previous hepatitis B vaccination, but all had antibody titres <10 mUI/mL. Patients were allotted to two groups: previous hepatitis B virus vaccination and no previous hepatitis B virus vaccination or anti-HBs titres <10 mUI/mL. Patients in both groups received 16 i.d. injections of 0.1 mL of hepatitis B virus vaccine over an eight-week period. Patients had antibody titres assessed before vaccination, 1 month after and every 3 months for a year. Antibody titres >/=10 mUI/mL were considered protective. Seventy patients completed the protocol. Protective titres were elicited in 82% of each group. Age, time under dialysis, diabetes, smoking and body-mass index were not associated with seroconversion. Persistent protective titres >12 months occurred in 27 (58.7%). Adverse events were trivial. Intradermal hepatitis B virus vaccination is an alternative in end-stage renal failure.
Subject: Adult
Aged, 80 And Over
Hepatitis B
Hepatitis B Vaccines
Injections, Intradermal
Kidney Failure, Chronic
Middle Aged
Prospective Studies
Renal Dialysis
Citation: Alimentary Pharmacology & Therapeutics. v. 25, n. 7, p. 849-55, 2007-Apr.
Rights: fechado
Identifier DOI: 10.1111/j.1365-2036.2007.03210.x
Date Issue: 2007
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_17373924.pdf460.2 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.